Authors
Radek Pudil, Christian Mueller, Jelena Čelutkienė, Peter A Henriksen, Dan Lenihan, Susan Dent, Ana Barac, Susanna Stanway, Javid Moslehi, Thomas M Suter, Bonnie Ky, Martin Štěrba, Daniela Cardinale, Alain Cohen‐Solal, Carlo Gabriele Tocchetti, Dimitrios Farmakis, Jutta Bergler‐Klein, Markus S Anker, Stephan Von Haehling, Yury Belenkov, Zaza Iakobishvili, Christoph Maack, Fortunato Ciardiello, Frank Ruschitzka, Andrew JS Coats, Petar Seferovic, Mitja Lainscak, Massimo F Piepoli, Ovidiu Chioncel, Jereon Bax, Jean‐Sebastien Hulot, Hadi Skouri, Eva Simona Hägler‐Laube, Riccardo Asteggiano, Teresa Lopez Fernandez, Rudolf A de Boer, Alexander R Lyon
Publication date
2020/11
Journal
European journal of heart failure
Volume
22
Issue
11
Pages
1966-1983
Publisher
John Wiley & Sons, Ltd.
Description
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio‐Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio‐Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two …
Scholar articles
R Pudil, C Mueller, J Čelutkienė, PA Henriksen… - European journal of heart failure, 2020